文献速递瓣膜外科

经心尖二尖瓣新腱索植入修复术的结局

Outcomes of transapical mitral valve repair with neochordae implantation.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-04-09

本研究报告了本中心2013年11月至2016年3月连续100例接受经心尖非体外循环心脏跳动下新腱索植入术的退行性二尖瓣反流患者的5年临床与超声结局。中位随访5.1年,技术成功98%、手术成功94%,30天死亡率2%。5年重度二尖瓣反流复发累积发生率在解剖条件良好组为14%(95%CI 6.5%-22.8%),在解剖条件不佳组为63%(95%CI 39.7%-86.2%)(P<.001)。作者认为该术式可能是有解剖条件良好患者的一种可接受选择。

要点

  • 连续100例退行性二尖瓣反流患者接受经心尖非体外循环心脏跳动下新腱索植入术,技术成功98%、手术成功94%。
  • 5年重度二尖瓣反流复发累积发生率在解剖条件良好组为14%(95%CI 6.5%-22.8%),在解剖条件不佳组为63%(95%CI 39.7%-86.2%)(P<.001)。
  • 作者认为该术式可能是有退行性二尖瓣病变且解剖条件良好患者的一种可接受选择。

核心结论

  • 作者认为经心尖非体外循环心脏跳动下新腱索植入术可能是退行性二尖瓣病变且解剖条件良好患者的一种可接受选择。

研究设计与样本

  • 本研究报告了本中心2013年11月至2016年3月连续100例接受经心尖非体外循环心脏跳动下新腱索植入术的退行性二尖瓣反流患者,数据前瞻性收集并回顾性分析,按二尖瓣病变范围和严重程度分为解剖条件良好组(81%)和解剖条件不佳组(19%)。

主要发现

  • 技术成功率为98%,手术成功率为94%,30天死亡率为2%。
  • 装置成功率在30天、1年和5年分别为94%、92%和78%,1年患者成功率为92%。
  • 中位随访5.1年,5年总生存率为83%,解剖条件良好组与解剖条件不佳组之间无差异。
  • 5年重度二尖瓣反流复发累积发生率在解剖条件良好组为14%(95%CI 6.5%-22.8%),在解剖条件不佳组为63%(95%CI 39.7%-86.2%)(P<.001)。
  • 解剖条件良好组与解剖条件不佳组相比再干预发生率更低(14.7% vs 43.4%;P<.001)。

关键数值与推荐

  • 适应证为因瓣叶脱垂或连枷导致的严重症状性退行性二尖瓣反流。
  • 结局评价基于二尖瓣瓣膜学术研究联盟(Mitral Valve Academic Research Consortium)指南。
  • 随访在1、3、6和12个月以及此后每年进行临床和超声随访。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Transapical off-pump beating-heart neochord implantation (NC) has shown encouraging early results in patients with degenerative mitral regurgitation. The aim of this study was to evaluate clinical and echocardiographic 5-year outcomes of patients who underwent NC. METHODS: All patients who underwent NC at our institution from November 2013 to March 2016 were included. Indications were severe symptomatic degenerative mitral regurgitation due to leaflet prolapse/flail. Patients were classified as having favorable anatomy (FA) and unfavorable anatomy (UA) on the basis of the extent and severity of mitral valve disease. All patients underwent clinical and echocardiographic follow-up at 1, 3, 6, and 12 months, and annually thereafter. Data were prospectively collected and retrospectively analyzed. Outcomes were on the basis of the Mitral Valve Academic Research Consortium guidelines. RESULTS: One hundred consecutive patients were included in the analysis (FA: 81%; UA: 19%). Median age was 66 years (interquartile range, 58-76) and median European System for Cardiac Operative Risk Evaluation (EuroSCORE) II was 1.4% (interquartile range, 0.7-2.3). Technical and procedural success were 98% and 94%, respectively. Thirty-day mortality was 2%. Device success was 94%, 92%, and 78%, at 30 days, 1-year, and 5 years, respectively. Patient success at 1 year was 92%. Median follow-up was 5.1 years. At 5 years, overall survival was 83% with no difference between FA and UA patients. Cumulative incidence of severe mitral regurgitation recurrence at 5 years was 14% (95% CI, 6.5%-22.8%) in FA patients and 63% (95% CI, 39.7%-86.2%) in UA patients, respectively (P < .001). Patients with FA compared with UA had a lower incidence of reintervention (14.7% vs 43.4%; P < .001). CONCLUSIONS: Transapical off-pump beating heart NC might represent an acceptable option in patients with degenerative mitral valve disease and FA.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. D'Onofrio A, Fiocco A, Nadali M, et al. Outcomes of transapical mitral valve repair with neochordae implantation. J Thorac Cardiovasc Surg. 2022. PMID: 35624055. doi:10.1016/j.jtcvs.2022.02.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。